Anticorps Polyclonal de lapin anti-EXOSC5

EXOSC5 Polyclonal Antibody for IHC, IP, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat

Applications

WB, IP, IHC, ELISA

Conjugaison

Non conjugué

Publications

3

Avis (2)

N° de cat : 15627-1-AP

Synonymes

CML28, EXOSC5, exosome component 5, hRrp46p, p12B, RRP41B, RRP46, Rrp46p

---

Galerie de données de validation

• 

  WB analysis using 15627-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 15627-1-AP (EXOSC5 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Raji using 15627-1-AP

  Raji cells were subjected to SDS PAGE followed by western blot with 15627-1-AP (EXOSC5 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 15627-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 15627-1-AP (EXOSC5 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HeLa using 15627-1-AP

  IP result of anti-EXOSC5 (IP:15627-1-AP, 4ug; Detection:15627-1-AP 1:300) with HeLa cells lysate 2800 ug.

• 

  IHC staining of human breast cancer using 15627-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 15627-1-AP (EXOSC5 antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 15627-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 15627-1-AP (EXOSC5 antibody) at dilution of 1:50 (under 40x lens).

---

Applications testées

• Résultats positifs en WB: cellules HEK-293, cellules HeLa, cellules K-562, cellules Raji
• Résultats positifs en IP: cellules HeLa,
• Résultats positifs en IHC: tissu de cancer du sein humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:3000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:20-1:200

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 2 publications below
• IHC: See 2 publications below

Informations sur le produit

15627-1-AP cible EXOSC5 dans les applications de WB, IP, IHC, ELISA et montre une réactivité avec des échantillons Humain, rat

• Réactivité: Humain, rat
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: EXOSC5 Protéine recombinante Ag8098
• Nom complet: exosome component 5
• Masse moléculaire calculée: 235 aa, 25 kDa
• Poids moléculaire observé: 28-30 kDa
• Numéro d’acquisition GenBank: BC007742
• Symbole du gène: EXOSC5
• Identification du gène (NCBI): 56915
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

CML28 is a component of the human exosome, which is a multiprotein complex involved in the 3′ processing and degradation of RNA [PMID:12359762]. CML28 is a novel 28 kDa TAA identified by serological analysis of cDNA expression libraries (SEREX) screening of a chronic myeloid leukemia (CML) cDNA expression library. As a potential target for tumor-specific immunotherapy, CML28 is superior to other known TAAs characterized by its broader spectrum expression in tumor cells and stricter expression in normal tissues [PMID:16815301].

Publications

Species	Application	Title
human	WB,IHC	J Cancer; EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways.; Authors - Xiangliu Chen
human	IHC	Int J Mol Sci; Integrated Bioinformatic Investigation of EXOSCs in Hepatocellular Carcinoma Followed by the Preliminary Validation of EXOSC5 in Cell Proliferation; Authors - Yujing Zhang
human	WB	Life Sci Alliance; Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication; Authors - Tobias Moll

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.

---

FH

Tsimafei (Verified Customer) (07-06-2022)

Reduction of Exosc5 is observed when comparing depletion vs control. Antibodies were incubated ON at 4C.

• Applications: Western Blot
• Primary Antibody Dilution: 1:5000
• Cell Tissue Type: mESCs

EXOSC5 Antibody Western Blot validation (1:5000 dilution) in mESCs (Cat no:15627-1-AP)

FH

Nikolaus (Verified Customer) (05-24-2022)

Depletion is a conditional KO time-course; strong cross-reactivity with Bio-Rad dual stain ladder (25 kDa band)

• Applications: Western Blot
• Primary Antibody Dilution: 1/2000
• Cell Tissue Type: mESC

EXOSC5 Antibody Western Blot validation (1/2000 dilution) in mESC (Cat no:15627-1-AP)